Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 6Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 4Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia 2Paraproteinemias 1Neoplasms, Plasma Cell 1Natural Killer/T-cell Lymphoma 1Lymphoproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Immunoproliferative Disorders 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 59fludarabine phosphate 52Peripheral Blood Stem Cell Transplantation 40Busulfan 39Tacrolimus 35Antilymphocyte Serum 34Mycophenolic Acid 33Radiotherapy 30Filgrastim 28Cyclosporine 25Melphalan 24Methotrexate 22Whole-Body Irradiation 21fludarabine 20Methylprednisolone 17Etoposide 16Cord Blood Stem Cell Transplantation 15sargramostim 9Rituximab 9Granulocyte Colony-Stimulating Factor 9Cytarabine 9Bortezomib 9Alemtuzumab 9Sirolimus 8Epoetin Alfa 7Psychiatric Rehabilitation 6Prednisone 6Flow Cytometry 6Carmustine 6Trimethoprim, Sulfamethoxazole Drug Combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × isatuximab × Lymphoid × Clear all
NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Pfizer

Phase 1 Terminated
189 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡